Abstract
A series of subtype selective sphingosine 1-phosphate receptor 1 (S1P(1)) antagonists are disclosed. Our high-throughput screening campaign revealed hit 1 for which an increase in potency and mouse oral exposure was achieved with minor modifications to the chemical scaffold. In vivo efficacy revealed that at high doses compounds 12 and 15 inhibited tumor growth. Further optimization of our lead series led to the discovery of proline derivatives 37 (XL541) and 38 which had similar efficacy as our first generation analogues at significantly lower doses. Analogue 37 displayed excellent pharmacokinetics and oral exposure in multiple species.
MeSH terms
-
Administration, Oral
-
Amides / chemical synthesis
-
Amides / pharmacokinetics
-
Amides / pharmacology
-
Angiogenesis Inhibitors / chemical synthesis
-
Angiogenesis Inhibitors / pharmacokinetics
-
Angiogenesis Inhibitors / pharmacology
-
Aniline Compounds / chemical synthesis
-
Aniline Compounds / pharmacokinetics
-
Aniline Compounds / pharmacology
-
Animals
-
Antineoplastic Agents / chemical synthesis*
-
Antineoplastic Agents / pharmacokinetics
-
Antineoplastic Agents / pharmacology
-
Biological Availability
-
Cell Line
-
Cell Proliferation / drug effects
-
Dogs
-
Haplorhini
-
High-Throughput Screening Assays
-
Mice
-
Neovascularization, Pathologic
-
Proline / analogs & derivatives
-
Proline / chemical synthesis
-
Proline / pharmacokinetics
-
Proline / pharmacology
-
Rats
-
Receptors, Lysosphingolipid / antagonists & inhibitors*
-
Serine / analogs & derivatives
-
Serine / chemical synthesis
-
Serine / pharmacokinetics
-
Serine / pharmacology
-
Stereoisomerism
-
Xenograft Model Antitumor Assays
Substances
-
Amides
-
Angiogenesis Inhibitors
-
Aniline Compounds
-
Antineoplastic Agents
-
Receptors, Lysosphingolipid
-
Serine
-
Proline